{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T13:03:26Z","timestamp":1778591006849,"version":"3.51.4"},"reference-count":26,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2019,1,17]],"date-time":"2019-01-17T00:00:00Z","timestamp":1547683200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["This study was sponsored by Pfizer Inc."],"award-info":[{"award-number":["This study was sponsored by Pfizer Inc."]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:p>Karyotype is frequently used to predict response and outcome in leukemia. This post hoc exploratory analysis evaluated the relationship between baseline cytogenetics and outcome in patients with relapsed\/refractory acute lymphoblastic leukemia (R\/R ALL) treated with inotuzumab ozogamicin (InO), a humanized CD22 antibody conjugated to calicheamicin, in the phase 3, open\u2010label, randomized INO\u2010VATE trial. Data as of March 8, 2016, are presented in this analysis. Of the 326 patients randomized, 284 had screening karyotyping data (144 in the InO arm and 140 in the standard care [SC] arm). With InO, complete remission or complete remission with incomplete hematologic recovery (CR\/CRi), minimal residual disease negativity rates, and overall survival (OS) were not significantly different between cytogenetic subgroups. CR\/CRi rates favored InO over SC in the diploid with \u226520 metaphases, complex, and \u201cother\u201d cytogenetic subgroups. The OS hazard ratio favored InO over SC in the diploid with \u226520 metaphases, complex, and <jats:italic>other<\/jats:italic> cytogenetic subgroups. Generally, InO is effective and provides substantial clinical benefit in patients with R\/R ALL who have specific baseline karyotypes.<\/jats:p>","DOI":"10.1002\/ajh.25394","type":"journal-article","created":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T08:26:35Z","timestamp":1547022395000},"page":"408-416","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin"],"prefix":"10.1002","volume":"94","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4465-6119","authenticated-orcid":false,"given":"Elias","family":"Jabbour","sequence":"first","affiliation":[{"name":"Department of Leukemia, University of Texas MD Anderson Cancer Center  Houston Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anjali S.","family":"Advani","sequence":"additional","affiliation":[{"name":"Leukemia Program, Cleveland Clinic  Cleveland Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Stelljes","sequence":"additional","affiliation":[{"name":"Department of Medicine A, Hematology and Oncology University of Muenster  Muenster Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy","family":"Stock","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology University of Chicago  Chicago Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8945-5850","authenticated-orcid":false,"given":"Michaela","family":"Liedtke","sequence":"additional","affiliation":[{"name":"Divisions of Hematology and Oncology Stanford Cancer Institute  Stanford California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"G\u00f6kbuget","sequence":"additional","affiliation":[{"name":"Department of Medicine Goethe University  Frankfurt Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Martinelli","sequence":"additional","affiliation":[{"name":"Institute Ser\u00e0gnoli, DIMES University of Bologna  Bologna Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2481-7504","authenticated-orcid":false,"given":"Susan","family":"O'Brien","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Chao Family Comprehensive Cancer Center University of California  Orange California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane Liang","family":"White","sequence":"additional","affiliation":[{"name":"Pfizer Inc  Groton Connecticut"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Wang","sequence":"additional","affiliation":[{"name":"Pfizer Inc  Groton Connecticut"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Luisa Paccagnella","sequence":"additional","affiliation":[{"name":"Pfizer Inc  Groton Connecticut"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Sleight","sequence":"additional","affiliation":[{"name":"Pfizer Inc  Groton Connecticut"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Vandendries","sequence":"additional","affiliation":[{"name":"Pfizer Inc  Cambridge Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J.","family":"DeAngelo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology\/Hematologic Malignancies Dana\u2010Farber Cancer Institute  Boston Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1908-3307","authenticated-orcid":false,"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"Department of Leukemia, University of Texas MD Anderson Cancer Center  Houston Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,1,17]]},"reference":[{"key":"e_1_2_8_2_1","first-page":"3135","article-title":"A collaborative study of the group Francais de Cytogenetique Hematologique","volume":"87","author":"Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic findings outcome","year":"1996","journal-title":"Blood"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.11.3995"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature09650"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra052603"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09095.x"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-529008"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509277"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71170-2"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2012.679359"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70386-2"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28136"},{"key":"e_1_2_8_13_1","first-page":"2574","article-title":"Inotuzumab ozogamicin (InO) vs standard of care (SC) in patients with relapsed\/refractory (R\/R) acute lymphoblastic leukemia (ALL): long\u2010term results of the phase 3 INO\u2010VATE study [abstract]","volume":"130","author":"Kantarjian HM","year":"2017","journal-title":"Blood"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.036"},{"key":"e_1_2_8_15_1","volume-title":"Recommendations of the International Standing Committee on Human Cytogenetic Nomenclature","author":"Shaffer LG","year":"2009"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-051912"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30376"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-04-1299"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-232124"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2532"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23901"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.10.008"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25953"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-012-0247-7"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609783"},{"key":"e_1_2_8_26_1","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood.V126.23.679.679","article-title":"Complete molecular and hematologic response in adult patients with relpased\/refractory (R\/R) Philadelphia chromosome\u2010positive B\u2010precursor acute lymphoblastic leukemia (ALL) following treatment with blinatumomab: results from a phase 2 single\u2010arm, multicenter study (ALCANTARA) [abstract]","volume":"126","author":"Martinelli G","year":"2015","journal-title":"Blood"},{"key":"e_1_2_8_27_1","doi-asserted-by":"crossref","unstructured":"SasakiK JabbourEJ O'BrienSM et al.Inotuzumab ozogamicin in combination with low\u2010intensity chemotherapy (mini\u2010hyper\u2010CVD) as frontline therapy for older patients with acute lymphoblastic leukemia (ALL): interim result of a phase II clinical trial. Paper presented at: American Society of Hematology 58th Annual Meeting & Exposition. San Diego CA.2016. Conference date: 3\u20106 December 2016.http:\/\/www.bloodjournal.org\/content\/128\/22\/588.","DOI":"10.1182\/blood.V128.22.588.588"}],"updated-by":[{"DOI":"10.1002\/ajh.26030","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T00:00:00Z","timestamp":1604361600000}}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.25394","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.25394","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajh.25394","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.25394","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T16:21:55Z","timestamp":1693930915000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.25394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,17]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["10.1002\/ajh.25394"],"URL":"https:\/\/doi.org\/10.1002\/ajh.25394","archive":["Portico"],"relation":{"correction":[{"id-type":"doi","id":"10.1002\/ajh.26030","asserted-by":"object"}]},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,17]]},"assertion":[{"value":"2018-07-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}